ADCT
4:05 PM
ADC Therapeutics Announces Results From LOTIS-5 Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Trial Results • Phase 3Topline results Wed, Jun 3, 2026adctherapeutics.com